Seikagaku and Ono Submit NDA for Injectable OA Treatment in Japan

Seikagaku and Ono Pharmaceutical submitted a new drug application (NDA) for manufacturing and marketing approval for ONO-5704/SI-613 injectable in Japan for the treatment of osteoarthritis in the knee, hip and ankle.

The NDA is based on the results of three Phase III clinical studies conducted in Japan.

ONO-5704/SI-613 is a combination...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us